Previous 10 | Next 10 |
2024-04-18 13:26:38 ET Summary Jazz Pharmaceuticals plc has a neuroscience franchise that is led by Xywav, which has replaced Xyrem as the top treatment for narcolepsy. The company's narcolepsy franchise is facing competition from Avadel Pharmaceuticals' Lumryz, but Jazz is defend...
2024-04-16 07:20:23 ET Reporting its Q1 2024 results, Big Pharma’s earnings bellwether, Johnson & Johnson ( NYSE: JNJ ), revised its full-year outlook below consensus on Tuesday after sales from its MedTech division fell short of Street forecasts.... Read the full a...
2024-04-12 23:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Captisol-enabled™ Topiramate Injection shown to be a substitute for an oral dose on a one-to-one basis Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Ca...
2024-04-05 13:53:08 ET More on Ovid Therapeutics Seeking Alpha’s Quant Rating on Ovid Therapeutics Historical earnings data for Ovid Therapeutics Financial information for Ovid Therapeutics Read the full article on Seeking Alpha For further det...
2024-04-03 09:23:59 ET More on Ligand Pharmaceuticals Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript Ligand Pharmaceuticals gains amid bullish investor pitch Ligand Pharmaceuticals Non-GAAP EPS of $1.05 beats by $0.39, revenue of $28.1M beats by ...
Pharmaceutical executive Scott Plesha named CEO Lead product ZELSUVMI expected to be commercially available in late 2024 Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of season...
2024-04-02 06:01:11 ET Summary Viking Therapeutics' share price has rapidly increased from recent weight loss drug excitement. The company’s value seems to be derived from its weight loss and NASH/MASH candidates. VK2735, the weight loss candidate, presents a potentiall...
2024-03-27 15:53:27 ET More on Ligand Pharmaceuticals Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript Ligand Pharmaceuticals Non-GAAP EPS of $1.05 beats by $0.39, revenue of $28.1M beats by $2.46M Ligand Pharmaceuticals Q4 2023 Earnings Preview ...
2024-03-24 00:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Ligand Pharmaceuticals Incorporated Website:
2024-07-30 06:30:09 ET RBC Capital analyst issues OUTPERFORM recommendation for LGND on July 30, 2024 03:16AM ET. LGND was trading at $108.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy recomm...
2024-07-30 06:00:04 ET Douglas Miehm from RBC Capital issued a price target of $130.00 for LGND on 2024-07-30 03:16:00. The adjusted price target was set to $130.00. At the time of the announcement, LGND was trading at $108.75. The overall price target consensus is at $1...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report second quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, August 6, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial resul...